1
|
Lyu J, Li T, Wang Q, Li F, Diao P, Liu L, Li C, Lang J. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study. Radiat Oncol 2018; 13:233. [PMID: 30477531 PMCID: PMC6257959 DOI: 10.1186/s13014-018-1183-y] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2018] [Accepted: 11/14/2018] [Indexed: 12/20/2022] Open
Abstract
Background The purpose of this study is to compare the efficacy and safety of concurrent chemoradiotherapy (CCRT) versus chemotherapy alone for patients with stage IV esophageal squamous cell carcinoma (ESCC). Methods Eligible patients were retrospectively enrolled at the authors’s institution from January 2010 to October 2015. Of the 141 patients enrolled, 55 (39.0%) received CCRT and 86 (61.0%) received chemotherapy alone. The outcomes and adverse events (AEs) were compared between the two groups. Results The baseline clinical characteristics of the two groups were similar. However, the CCRT group showed a significantly better primary tumor objective response rate (ORR) than that of the chemotherapy group (74.5% versus 45.3%, p = 0.001). The 1-year, 2-year, 3-year overall survival (OS) rates and median OS were 58.0% versus 43.0%, 25.5% versus 14.0%, 10.7% versus 4.7%, and 14 months versus 11 months for patients treated with CCRT or chemotherapy, respectively (p = 0.007). The 1-year and median progression-free survival (PFS) were 29.8% versus 14.9% and 8 months versus 6 months (p = 0.005). Multivariate analysis identified CCRT (p = 0.013) and solitary metastasis (p = 0.037) as independent factors for greater OS. The frequency of leucocytopenia (grade 3 or higher) was significantly higher in the CCRT group than in the chemotherapy-alone group (p = 0.040), whereas the rates of other AEs did not differ. Conclusions In this study, it is suggested that CCRT is more effective than chemotherapy alone for stage IV ESCC, yielding better primary responses and survival outcomes with tolerable side effects.
Collapse
Affiliation(s)
- Jiahua Lyu
- Department of Radiation Oncology, Sichuan Cancer hospital institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No.55, 4th section of Renmin South Road Chengdu, Chengdu, 610041, Sichuan Province, People's Republic of China
| | - Tao Li
- Department of Radiation Oncology, Sichuan Cancer hospital institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No.55, 4th section of Renmin South Road Chengdu, Chengdu, 610041, Sichuan Province, People's Republic of China.
| | - Qifeng Wang
- Department of Radiation Oncology, Sichuan Cancer hospital institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No.55, 4th section of Renmin South Road Chengdu, Chengdu, 610041, Sichuan Province, People's Republic of China
| | - Fang Li
- Department of Radiation Oncology, Sichuan Cancer hospital institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No.55, 4th section of Renmin South Road Chengdu, Chengdu, 610041, Sichuan Province, People's Republic of China
| | - Peng Diao
- Department of Radiation Oncology, Sichuan Cancer hospital institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No.55, 4th section of Renmin South Road Chengdu, Chengdu, 610041, Sichuan Province, People's Republic of China
| | - Li Liu
- Department of Radiation Oncology, Sichuan Cancer hospital institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No.55, 4th section of Renmin South Road Chengdu, Chengdu, 610041, Sichuan Province, People's Republic of China
| | - Churong Li
- Department of Radiation Oncology, Sichuan Cancer hospital institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No.55, 4th section of Renmin South Road Chengdu, Chengdu, 610041, Sichuan Province, People's Republic of China
| | - Jinyi Lang
- Department of Radiation Oncology, Sichuan Cancer hospital institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No.55, 4th section of Renmin South Road Chengdu, Chengdu, 610041, Sichuan Province, People's Republic of China
| |
Collapse
|
2
|
Dupic G, Biau J, Bellière-Calandry A, Lapeyre M. [Hypofractionated stereotactic body radiation therapy for adrenal metastases]. Cancer Radiother 2017; 21:404-410. [PMID: 28684242 DOI: 10.1016/j.canrad.2017.05.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2017] [Revised: 04/21/2017] [Accepted: 05/02/2017] [Indexed: 10/19/2022]
Abstract
Adrenal glands are a common site for metastatic spread since they represent the fourth metastatic site of solid tumors. Interest in local ablative treatments of oligometastases is growing since literature suggests better progression-free survival, quality of life and potentially overall survival in selected patients. Surgery remains the first treatment of adrenal oligometastases because results are good, with a long enough follow-up. However, stereotactic radiotherapy appears to be comparable to surgery and could be proposed to elderly, unfit, inoperable patients, or even to patients whose systemic treatment should not be suspended for too long. This article aims to present a review of published studies to date on stereotactic radiotherapy of adrenal metastases and to propose a treatment protocol.
Collapse
Affiliation(s)
- G Dupic
- Département de radiothérapie, centre Jean-Perrin, 58, rue Montalembert, 63000 Clermont-Ferrand, France.
| | - J Biau
- Département de radiothérapie, centre Jean-Perrin, 58, rue Montalembert, 63000 Clermont-Ferrand, France
| | - A Bellière-Calandry
- Département de radiothérapie, centre Jean-Perrin, 58, rue Montalembert, 63000 Clermont-Ferrand, France
| | - M Lapeyre
- Département de radiothérapie, centre Jean-Perrin, 58, rue Montalembert, 63000 Clermont-Ferrand, France
| |
Collapse
|
4
|
Riou O, Llacer Moscardo C, Fenoglietto P, Deshayes E, Tetreau R, Molinier J, Lenglet A, Assenat E, Ychou M, Guiu B, Aillères N, Bedos L, Azria D. SBRT planning for liver metastases: A focus on immobilization, motion management and planning imaging techniques. Rep Pract Oncol Radiother 2017; 22:103-110. [PMID: 28490980 DOI: 10.1016/j.rpor.2017.02.006] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2016] [Revised: 01/05/2017] [Accepted: 02/25/2017] [Indexed: 02/08/2023] Open
Abstract
AIM To evaluate the different techniques used for liver metastases Stereotactic Body Radiation Therapy (SBRT) planning. We especially focused on immobilization devices, motion management and imaging used for contouring. BACKGROUND Although some guidelines exist, there is no consensus regarding the minimal requirements for liver SBRT treatments. MATERIALS AND METHODS We reviewed the main liver metastases SBRT publications and guidelines; and compared the techniques used for immobilization, motion management, margins and imaging. RESULTS There is a wide variety of techniques used for immobilization, motion management and planning imaging. CONCLUSIONS We provide a subjective critical analysis of minimal requirements and ideal technique for liver SBRT planning.
Collapse
Affiliation(s)
- Olivier Riou
- Institut Régional du Cancer de Montpellier, ICM-Val d'Aurelle, Rue de la Croix Verte, Montpellier, France
| | - Carmen Llacer Moscardo
- Institut Régional du Cancer de Montpellier, ICM-Val d'Aurelle, Rue de la Croix Verte, Montpellier, France
| | - Pascal Fenoglietto
- Institut Régional du Cancer de Montpellier, ICM-Val d'Aurelle, Rue de la Croix Verte, Montpellier, France
| | - Emmanuel Deshayes
- Institut Régional du Cancer de Montpellier, ICM-Val d'Aurelle, Rue de la Croix Verte, Montpellier, France
| | - Raphaël Tetreau
- Institut Régional du Cancer de Montpellier, ICM-Val d'Aurelle, Rue de la Croix Verte, Montpellier, France
| | - Jessica Molinier
- Institut Régional du Cancer de Montpellier, ICM-Val d'Aurelle, Rue de la Croix Verte, Montpellier, France
| | - Alexis Lenglet
- Institut Régional du Cancer de Montpellier, ICM-Val d'Aurelle, Rue de la Croix Verte, Montpellier, France
| | - Eric Assenat
- Institut Régional du Cancer de Montpellier, ICM-Val d'Aurelle, Rue de la Croix Verte, Montpellier, France.,CHU Saint Eloi, 80 Avenue Augustin Fliche, 34090 Montpellier, France
| | - Marc Ychou
- Institut Régional du Cancer de Montpellier, ICM-Val d'Aurelle, Rue de la Croix Verte, Montpellier, France.,CHU Saint Eloi, 80 Avenue Augustin Fliche, 34090 Montpellier, France
| | - Boris Guiu
- CHU Saint Eloi, 80 Avenue Augustin Fliche, 34090 Montpellier, France
| | - Norbert Aillères
- Institut Régional du Cancer de Montpellier, ICM-Val d'Aurelle, Rue de la Croix Verte, Montpellier, France
| | - Ludovic Bedos
- Institut Régional du Cancer de Montpellier, ICM-Val d'Aurelle, Rue de la Croix Verte, Montpellier, France
| | - David Azria
- Institut Régional du Cancer de Montpellier, ICM-Val d'Aurelle, Rue de la Croix Verte, Montpellier, France
| |
Collapse
|
5
|
Abstract
Indication, doses, and technique of radiotherapy, for intrathoracic metastases are presented. The recommendations for delineation of the target volumes and organs at risk are detailed.
Collapse
Affiliation(s)
- P Giraud
- Service d'oncologie radiothérapie, hôpital européen-Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Université Paris-Descartes, Paris-Cité Sorbonne, 12, rue de l'École-de-Médecine, 75006 Paris, France.
| | - T Lacornerie
- Service de physique médicale, centre Oscar-Lambret, 3, avenue Frédéric-Combemale, 59000 Lille, France
| | - F Mornex
- EMR 3738, université Claude-Bernard Lyon 1, 165, chemin du Grand-Revoyet, 69310 Pierre-Bénite, France; Département de radiothérapie-oncologie, centre hospitalier Lyon Sud, 165, chemin du Grand-Revoyet, 69310 Pierre-Bénite, France
| |
Collapse
|